




Supplementary Fig. S1. Identification of RA-FLSs.

A: Immunofluorescence staining was carried out for RA-FLSs. The FLSs marker Vimentin and myofibroblast marker α -SMA were separately labelled with FITC ((Scale bars = 50 μ m).

B: Flow cytometry was performed for RA-FLSs. The FLSs were CD90, CD146, CD73, and CD44 positive.

Supplementary Fig. 2. The correlation between OPG fold change and IL-13R α 1 and IL-13R α 2. The OPG protein fold change correlates positively with IL-13 receptor α 1 RNA expression but shows no correlation with IL-13 receptor α 2 RNA expression (n=5).

Supplementary Table S1. The baseline clinical characteristics of the included patients.

no.	Age (years)	Gender	Duration (years)	CRP (mg/L)	ESR (mm/h)	Anti-CCP $_{\S}$	RF $_{\S}$	Radio- graphic changes
RASF1	55	female	>10	19.7	31	+	+	+
RASF2	70	female	>10	17.2	16	+	NA $_{\S}$	+
RASF3	37	male	1.5	27	23.8	NA	+	+
RASF4	50	female	3	29	3.8	NA	+	+
RASF5	64	female	15	29.9	23	+	+	+
RASF6	54	male	>10	35.7	38	+	+	+
RASF7	66	female	20	2.3	28	NA	+	+

$_{\S}$ CCP: cyclic citrullinated peptide; RF: rheumatoid factor; NA: not available